PillRx only · Injection, Solution · Subcutaneous
Adalimumab-Adaz
Brands: Adalimumab · Hyrimoz · Adalimumab
2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US15 NDCs
2 active makers
2 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 1 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$1586.921
Latest avg · Jul 22, 2026
-0%
Since Dec 17, 2025
2
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
13K
Rx · 2026 Q1
14K
Units dispensed
+229%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it2 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Sandoz Inc | unknown | 13 | SUPPLYING |
| Cordavis Limited | unknown | 7 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Jan 13, 2026RESOLVEDShortage resolved: Adalimumab-adaz Injection (Sandoz Inc.)
Adalimumab-adaz Injection — reported in shortage by Sandoz Inc.. Therapeutic category: Rheumatology.
- Jan 13, 2026SHORTAGEDrug shortage: Adalimumab-adaz Injection (Sandoz Inc.)
Adalimumab-adaz Injection — reported in shortage by Sandoz Inc.. Therapeutic category: Rheumatology.